RxDoctor Payments DataLook up a doctor →

Thomas Nugent, MD

Pulmonary Disease · Marlton, NJNPI 1457321044

Payments from drug & device makers

$20,144in general payments, 2019–2025

Across 637 payments — averaging $31.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$5K
  • AstraZeneca$5K
  • GSK$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Jazz Pharmaceuticals Inc.$800
  • Regeneron Healthcare Solutions, Inc.$795
  • plus $6K from 41 others

What the payments were for

  • Speaking & faculty fees$5,95033%
  • Food & beverage$11,50765%
  • Education$3602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,144 in reported general payments places this provider in the 85th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$232,656
Medicare patients
706
Services billed
2,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter217$235,033
OfevNintedanib Esylate11$170,084
OpsumitMacitentan12$151,394
Dupixent SyringeDupilumab17$62,520
Breo ElliptaFluticasone/Vilanterol61$49,797
EliquisApixaban46$47,789
Ambrisentan12$47,366
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$32,752
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$21,486
Stiolto RespimatTiotropium Br/Olodaterol Hcl27$17,234
Incruse ElliptaUmeclidinium Bromide25$17,192
SymbicortBudesonide/Formoterol Fumarate48$14,693
Albuterol Sulfate HfaAlbuterol Sulfate247$11,889
Fluticasone-SalmeterolFluticasone Propion/Salmeterol57$10,149
Wixela InhubFluticasone Propion/Salmeterol27$5,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$1,675$323,508323 claims
Boehringer IngelheimOfev, Stiolto Respimat$456$187,31838 claims
Actelion Pharmaceuticals US, Inc.Opsumit$704$151,39412 claims
PfizerEliquis$5,156$47,78946 claims
AstraZenecaBreztri Aerosphere, Symbicort$4,770$47,44580 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Marlton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →